Devyser launches the first IVDR compliant NGS assay for thalassemia and sickle cell disease testing
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
News | May 4, 2016
Devyser Holding AB announced at its annual general meeting yesterday the appointment of two new board members, Ernst Westman and Lars Höckenström.
Ernst Westman is CEO of the boule diagnostics group since 22 years. Lars Höckenström is currently a senior adviser at Stockholm corporate finance. Chairman of the board Mia Arnhult comments:
"I am delighted to have Ernst Westman and Lars Höckenström on Devyser’s board. Their combined experience and expertise within both the diagnostics industry and finance will greatly benefit our work.
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
Read More
Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has...
Read More
Devyser today announced that it entered a strategic agreement with Illumina, a global leader in DNA...
Read More
Devyser is proud to announce that the company has been awarded a tender by Oslo University Hospital...
Read More